The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 15, 2022

Filed:

Aug. 31, 2017
Applicant:

Agency for Science, Technology and Research, Singapore, SG;

Inventors:

Florent Ginhoux, Singapore, SG;

Chi Ee Peter See, Singapore, SG;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/569 (2006.01); A61K 35/15 (2015.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
G01N 33/56972 (2013.01); A61K 35/15 (2013.01); C07K 16/2803 (2013.01); C07K 16/2851 (2013.01); C07K 16/2863 (2013.01); C07K 16/2878 (2013.01); C07K 16/2896 (2013.01); G01N 2333/70503 (2013.01); G01N 2333/70578 (2013.01); G01N 2333/70596 (2013.01); G01N 2333/71 (2013.01);
Abstract

Biomarkers for the detection and identification of a precursor of conventional dendritic cell (cDC) (pre-DC) and its cell subsets (pre-cDC1 or pre-cDC2), are defined, which include CD169, CD327, AXL, CD271, CD324 and combinations thereof for detecting pre-DCs. Methods for detecting a disease or condition, prognosis of an existing disease or condition comprising determining the number of pre-DC cells in sample from a subject as compared to control, as well as methods of treating a patient comprising administration of antibodies against CD169, CD327, AXL, CD271, CD324 and combinations thereof are also disclosed. In addition, an immunogenic composition comprising one or more binding molecules specific for one or more biomarkers or antigen of a target disease and/or one or more cells selected from the group consisting of early pre-DC, pre-cDC1 and pre-cDC2 are also disclosed for eliciting an immune response against an infectious disease or cancer.


Find Patent Forward Citations

Loading…